New generation
NAD profiling

The most advanced, quick, and accurate NAD measuring technology

Contact us

Groundbreaking Technology

Measure ALL 4 forms of NAD directly from blood

Using the method of HIGHEST ACCURACY
on the market

With
RESULTS IN HOURS
rather than weeks

At a much
LOWER TOTAL COST

Products & Services



Q-NADMED blood and Q-NAD kits

Kits to measure NADs from any sample type



LABORATORY SERVICE

Laboratory service to support research and drug development

Science Behind NADMED

After years of study and development, NADMED brings to market a reliable yet simple technology for extracting and measuring all four NADs and two glutathiones. The technology is based on an accurate colorimetric quantification that can be performed even from a minuscule amount of blood. The NADMED method’s key advantage is that it can measure metabolites individually, unlike any other method. The NADMED method is based on solid scientific research from the University of Helsinki.

Why NADMED?

The NAD metabolite extraction system developed by NADMED is the only method to measure all four NADs and glutathiones (i.e. REDOX metabolites). Also, the key advantages of NADMED technology are accuracy, high throughput, low cost, reduced hands-on time, and small sample volume.

NADMED Story

The demand for a quick and reliable test method has rapidly increased over the past few years as researchers have found more links between NAD levels and various diseases. The lack of a reliable, quick, and cost-effective method was the driving force in developing a new technology to answer this call, which all started in the ASW Laboratory at the University of Helsinki, Finland.

Unlock the Secrets of NADs

NADMED has developed a groundbreaking method that significantly enhances the development of research and clinical care of many medical disorders, starting with mitochondrial diseases. NAD levels are believed to correspond with several metabolic and degenerative diseases. First promising results of using NAD boosters as therapy for Parkinson’s disease and mitochondrial myopathy have been recently published.